DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Dacetuzumab
Dacetuzumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
New Biological Therapies: Introduction to the Basis of the Risk of Infection
B-Cell Targets to Treat Antibody-Mediated Rejection In
(12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al
Monoclonal Antibodies in Myeloma
The Two Tontti Tudiul Lui Hi Ha Unit
Monoclonal Antibody-Based Therapy As a New Treatment Strategy in Multiple Myeloma
Distinct Apoptotic Signaling Characteristics of the Anti-CD40
(INN) for Biological and Biotechnological Substances
Ep 3321281 A1
Novel Drugs in the Pipeline
Seattle Genetics Likely to Remain Attractive
WO 2018/107109 Al 14 June 2018 (14.06.2018) W !P O PCT
Agonistic CD40 Antibodies and Cancer Therapy
INN Working Document 05.179 Update 2011
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
Redalyc.Advances in the Diagnosis and Control of Lymphomas
Top View
(INN) for Biological and Biotechnological Substances
Managing Relapsed and Refractory DLBCL
Treatment of DLBCL
Ranjana H. Advani, MD
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Novel Antibodies in the Treatment of Non-Hodgkin's Lymphoma
Pharmaceutical Appendix to the Tariff Schedule 2
Ranjana Advani Saul A
How I Treat Relapsed/Refractory Disease – DLBCL and CLL
N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
Patent Application Publication Oo) Pub. No.: US 2015/0322155 Al Zhao (43) Pub
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: a Systematic Review of Agents Under Clinical Development
Mechanisms of Resistance to Monoclonal Antibodies (Mabs) in Lymphoid Malignancies
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
New Antibody Approaches to Lymphoma Therapy Tejas Suresh1, Lisa X Lee1, Jitesh Joshi1 and Stefan K Barta2*
Monoclonal Antibodies in the Treatment of Multiple Myeloma: Current Status and Future Perspectives
Modeling Hepatocellular Toxicity of Enavatuzumab, a Humanized Anti-Tweakr Antibody
Development of CD40-Targeted Bifunctional Scfv-TRAIL Fusion Proteins That Induce TRAILR1- and TRAILR2-Specifc Cell Death and Dendritic Cells Activation
Targeted Radionuclide Therapy: Proceedings of the 2Nd NCI-SNMMI Workshop On
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
WO 2016/094505 Al 16 June 2016 (16.06.2016) W P O P C T
Characteristics and Clinical Trial Results of Agonistic Anti‑CD40 Antibodies in the Treatment of Malignancies (Review)
Regulation (EU) No 1238/2010 of the European Parliament
The Honorable Shara Aranoff Chairman United States International Trade Commission 500 E Street, S.W. Washington, DC 20436 Dear C
Tłumaczenie Patentu Europejskiego (19) Pl (11) Pl/Ep 3129406 Polska
SG040-0005 Synopsis
International Journal of Current Advanced Research
Proapoptotic Signaling Activity of the Anti-CD40 Monoclonal Antibody Dacetuzumab Circumvents Multiple Oncogenic Transformation Events and Chemosensitizes NHL Cells
Activated B-Cell
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
(12) Patent Application Publication (10) Pub. No.: US 2011/0300186 A1 Hellstrom Et Al
Protein-Polymer-Drug Conjugates Protein-Polymer-Wirkstoffkonjugate Conjugués De Médicament-Protéine-Polymère
Development and Optimization of Peptide-Based, Tumor-Associated Macrophage (TAM)-Targeting Therapeutics
Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
Agonistic CD40 Antibodies in Cancer Treatment
(INN) for Biological and Biotechnological Substances
Medicines & Vaccines in Development for Cancer
A Phase II Study of Dacetuzumab (SGN-40) in Patients with Relapsed
Distinct Apoptotic Signaling Characteristics of the Anti-CD40
A Phase I Multidose Study of Dacetuzumab (SGN-40; Humanized Anti-CD40 Monoclonal Antibody) in Patients with Multiple Myeloma
Pomalidomide in Relapsed/Refractory Multiple Myeloma – Trial Overview
Ep 3088005 A1
Ppt0000022 [Tryb Zgodności]
WO 2017/215590 Al 21 December 2017 (21.12.2017) W !P O PCT
Assessment of the Evolution of Cancer Treatment Therapies
Timepoint 1 Geting Assembly Complexes (Attacs) for Selectively Activating De¬ Sired Immune Cells in the Tumor Microenvironment
Us 2019 / 0127401 A1
The Evolution in the Treatment of Multiple Myeloma Towards Targeted Magnetic Molecularly Imprinted Nanomedicines Edgar Pérez-Herrero
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al
Human BMPR1B Amino Acid Sequence
Cadth Pcodr Final Clinical Guidance Report